Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study

INTRODUCTION: B-cell-depleting agents have been widely used for neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated diseases (MOGAD), but no consensus exists on the optimal dose and frequency of treatment administration. The aim of our study was to evaluate the effect of a Rituximab (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruschi, Nicolò, Malentacchi, Maria, Malucchi, Simona, Sperli, Francesca, Martire, Serena, Sala, Arianna, Valentino, Paola, Bertolotto, Antonio, Pautasso, Marisa, Capobianco, Marco Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310632/
https://www.ncbi.nlm.nih.gov/pubmed/37166677
http://dx.doi.org/10.1007/s40120-023-00481-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310632/
https://www.ncbi.nlm.nih.gov/pubmed/37166677
http://dx.doi.org/10.1007/s40120-023-00481-w

Ejemplares similares